Equities

United Therapeutics Corp

United Therapeutics Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)400.87
  • Today's Change0.43 / 0.11%
  • Shares traded356.95k
  • 1 Year change+79.89%
  • Beta0.5676
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.

  • Revenue in USD (TTM)2.76bn
  • Net income in USD1.11bn
  • Incorporated1996
  • Employees1.17k
  • Location
    United Therapeutics Corp1000 SPRING STSILVER SPRING 20910United StatesUSA
  • Phone+1 (301) 608-9292
  • Fax+1 (301) 608-9291
  • Websitehttps://www.unither.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Revolution Medicines Inc742.00k-567.06m10.19bn490.00--6.49--13,738.67-3.59-3.590.00479.340.0005--4.801,962.96-41.28-29.76-44.46-32.59-----76,423.31-606.93----0.00---67.27-10.50-75.46--38.82--
Exelixis Inc2.08bn466.92m10.34bn1.31k23.064.5520.904.961.571.576.927.960.70123.398.041,589,006.0015.738.8618.089.9196.2596.3022.4315.433.88--0.000.0013.6016.4713.98-21.343.98--
Sarepta Therapeutics Inc1.64bn121.85m11.26bn1.31k96.909.2270.146.861.221.2216.3012.790.4890.57034.351,248,362.003.63-21.634.38-25.7585.9286.657.43-77.053.03--0.5013--33.2632.8023.81--6.30--
Charles River Lbrtrs ntrntl Inc4.06bn413.08m11.29bn20.00k27.552.9814.692.788.018.0178.6373.970.52038.275.23203,045.805.486.466.337.6235.9336.9910.5411.581.144.960.37840.003.8612.75-2.3916.6917.86--
Medpace Holdings Inc2.07bn365.57m11.30bn5.90k31.8412.7928.655.4611.4211.4264.7028.421.16--6.85350,994.3020.4813.9443.5123.1829.6928.8417.6615.23----0.00--29.1721.7615.2631.1717.99--
BIO-TECHNE Corp1.17bn150.68m11.87bn3.10k79.445.5545.2910.130.94020.94027.2913.460.42672.155.47377,930.005.499.425.7710.0465.9367.2912.8621.413.2618.070.12322.791.9710.17-41.0711.8619.870.00
Tempus AI Inc640.44m-800.71m12.22bn2.30k--224.39--19.08-8.29-8.294.440.3459----------------53.18---116.06--2.55-14.950.891--65.85--20.35------
Insmed Inc342.96m-864.29m12.85bn912.00--26.57--37.46-5.56-5.562.212.700.20310.88488.81376,050.40-51.17-40.96-59.16-46.8877.2577.99-252.01-212.925.99-18.410.6702--24.3998.78-55.66---2.15--
Neurocrine Biosciences, Inc.2.24bn385.90m12.88bn1.70k34.064.7331.285.743.733.7321.6726.870.70270.89014.991,602,000.0012.099.7714.6712.1998.5298.5117.2114.794.2610.280.00--26.7633.1361.6263.902.67--
Vaxcyte Inc0.00-507.65m12.92bn254.00--3.77-----4.55-4.550.0027.470.00----0.00-20.08-34.22-20.95-37.21------------0.00-------80.00--107.28--
Summit Therapeutics Inc0.00-196.68m16.05bn105.00--36.64-----0.2768-0.27680.000.59410.00----0.00-54.53-77.32-71.71-86.35-------20,989.46----0.053---100.00---680.54---4.84--
Moderna Inc5.08bn-2.22bn16.43bn5.60k--1.38--3.23-5.81-5.8113.1430.980.28832.442.96907,321.40-12.6220.95-15.5229.5178.43---43.7732.104.20--0.05210.00-64.45119.28-156.37--46.22--
ICON PLC8.31bn747.89m17.52bn42.25k23.591.7913.582.118.998.9999.87118.390.4852--2.99202,112.504.373.935.244.8029.6328.919.007.37--4.410.2599--4.8925.6221.1813.6723.79--
United Therapeutics Corporation2.76bn1.11bn17.88bn1.17k17.602.9315.186.4922.7522.7556.36136.740.38972.439.182,359,760.0015.7110.3817.7311.2788.9491.4740.3129.254.41--0.06150.0020.207.4135.4010.894.55--
Data as of Nov 12 2024. Currency figures normalised to United Therapeutics Corp's reporting currency: US Dollar USD

Institutional shareholders

51.92%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 30 Jun 20244.38m9.84%
The Vanguard Group, Inc.as of 30 Jun 20244.36m9.79%
Avoro Capital Advisor LLCas of 30 Jun 20242.86m6.43%
Wellington Management Co. LLPas of 30 Jun 20242.74m6.15%
SSgA Funds Management, Inc.as of 30 Sep 20242.24m5.03%
Renaissance Technologies LLCas of 30 Jun 20242.17m4.89%
Citigroup Global Markets, Inc. (Investment Management)as of 30 Jun 20241.62m3.64%
Geode Capital Management LLCas of 30 Jun 20241.05m2.36%
LSV Asset Managementas of 30 Jun 2024966.37k2.17%
AQR Capital Management LLCas of 30 Jun 2024719.51k1.62%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.